Report Code: CMI44559

Published Date: March 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 6.6%
8.7B
2023
9.2B
2024
21.3B
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Bayer AG
  • BD (Becton Dickinson and Company)
  • Bio-Rad Laboratories Inc.
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Liver Cancer Diagnostics Market is expected to record a CAGR of 6.6% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 9.2 Billion. By 2033, the valuation is anticipated to reach USD 21.3 Billion.

The Liver Cancer Diagnostics market encompasses the range of medical tests, imaging techniques, and biomarker assays used to detect and diagnose liver cancer. Its nature involves the integration of advanced technologies such as imaging modalities and molecular diagnostics to identify tumors and assess disease progression.

Current trends emphasize the shift towards personalized medicine, including the use of genetic and biomarker-based tests, as well as the integration of artificial intelligence for improved diagnostic accuracy and treatment planning in liver cancer management.

Liver Cancer Diagnostics Market – Parent Market Analysis

Market Name 2023
Cancer Diagnostics Market 20299.4
Liver Cancer Diagnostics Market 8718

Liver Cancer Diagnostics Market – Significant Growth Factors

The Liver Cancer Diagnostics Market presents significant growth opportunities due to several factors:

  • Rising Incidence of Liver Cancer: The increasing prevalence of risk factors such as hepatitis B and C infections, alcohol consumption, and obesity is a key driver. Opportunities lie in developing robust screening programs and diagnostic tools to detect liver cancer at early stages, improving patient outcomes and reducing mortality rates.
  • Technological Advancements: Continuous advancements in imaging technologies, such as MRI, CT scans, and ultrasound, offer opportunities to enhance diagnostic accuracy. Integrating artificial intelligence and machine learning algorithms can further refine diagnostic capabilities, enabling early detection and precise treatment planning, ultimately improving patient care and prognosis.
  • Growing Adoption of Biomarker-Based Tests: The shift towards personalized medicine has spurred the development and adoption of biomarker-based tests for liver cancer diagnosis. Opportunities exist in identifying novel biomarkers that can accurately predict disease progression, treatment response, and recurrence, facilitating personalized treatment strategies and improving patient outcomes.
  • Increasing Awareness and Screening Initiatives: Rising awareness about the importance of early detection and screening for liver cancer presents opportunities for healthcare providers and diagnostic companies. Collaborating with healthcare organizations to implement comprehensive screening programs and educational initiatives can drive demand for liver cancer diagnostic tests, leading to timely interventions and improved patient survival rates.
  • Expanding Healthcare Infrastructure in Emerging Markets: The improving healthcare infrastructure and increasing access to healthcare services in emerging markets present opportunities for market expansion. Companies can capitalize on these opportunities by offering cost-effective and scalable diagnostic solutions tailored to the needs of these regions, addressing the unmet needs of underserved populations and driving market growth.
  • Strategic Collaborations and Partnerships: Collaborations between diagnostic companies, research institutions, and healthcare organizations offer opportunities for innovation and market expansion. By leveraging each other’s expertise and resources, companies can accelerate the development and commercialization of novel diagnostic technologies, expand their market presence, and address evolving customer needs more effectively, driving growth in the liver cancer diagnostics market.

Liver Cancer Diagnostics Market – Mergers and Acquisitions

The liver cancer diagnostics market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the liver cancer diagnostics market include:

  • In January 2022, Thermo Fisher Scientific, Inc. forged a collaboration with OncoCyte Corporation, a California-based diagnostics firm. This partnership aims to broaden Thermo Fisher’s range of in-vitro diagnostics assays, particularly in the field of precision oncology.
  • In August 2021, Illumina, Inc. disclosed its acquisition of GRAIL, a healthcare entity specializing in early cancer detection. Notably, Illumina plans to maintain GRAIL as a separate entity during the ongoing regulatory scrutiny by the European Commission.
  • In September 2021, BDR Pharma, headquartered in India, unveiled the release of Cabozantinib, a generic cancer medication. This drug, recognized for its efficacy in treating hepatocellular carcinoma and various other cancers, marks a significant milestone in BDR Pharma’s oncological offerings.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the liver cancer diagnostics market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Liver Cancer Diagnostics Market Penile Cancer Treatment Market Personalized Cancer Medicine Market
CAGR 6.6% (Approx) CAGR 7.8% (Approx) CAGR 8.2% (Approx)
USD 21.3 Billion by 2032 USD 12.9 Billion by 2033 USD 707.1 Billion by 2033

Liver Cancer Diagnostics Market – Significant Threats

The liver cancer diagnostics market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Limited Awareness and Access to Healthcare: In regions with poor healthcare infrastructure and limited access to diagnostic services, many cases of liver cancer may go undetected or diagnosed at later stages, posing a threat to patient outcomes and market growth.
  • High Cost of Advanced Diagnostics: Advanced imaging modalities and molecular diagnostic tests for liver cancer can be expensive, limiting their accessibility to certain patient populations and healthcare systems. This cost barrier may hinder market penetration and adoption of these technologies.
  • Regulatory Challenges and Compliance: Stringent regulatory requirements for approval and commercialization of liver cancer diagnostic tests can lead to delays in product launches and increased compliance costs for companies. Adhering to regulatory standards while maintaining competitiveness poses a challenge to market players.
  • Competition from Alternative Diagnostic Modalities: Alternative diagnostic methods, such as biopsy and imaging techniques like MRI and CT scans, pose a threat to the market for liver cancer diagnostics. These traditional approaches may continue to be preferred by clinicians and patients, limiting the uptake of novel diagnostic technologies.
  • Emerging Technologies and Disruptive Innovations: Rapid advancements in technology and the emergence of disruptive innovations in the field of diagnostics present a threat to established players in the liver cancer diagnostics market. Companies must continually innovate and adapt to stay ahead of competitors and maintain market relevance.
  • Global Economic Uncertainty: Economic downturns, geopolitical instability, and healthcare budget constraints can impact spending on healthcare services and diagnostics, potentially slowing market growth for liver cancer diagnostics. Uncertainties in reimbursement policies and healthcare funding pose challenges to market expansion efforts.

Global Liver Cancer Diagnostics Market 2024–2033 (By Test Type)

www.custommarketinsight.com

Category-Wise Insights

By Test Type

  • AFP Tests (Alpha-fetoprotein Tests): AFP tests measure the levels of alpha-fetoprotein in the blood, a protein associated with liver cancer. It aids in screening, diagnosis, and monitoring of liver cancer progression. Trends include the integration of AFP tests into multi-marker panels for improved accuracy, as well as the development of novel assays with enhanced sensitivity and specificity.
  • LFTs (Liver Function Tests): LFTs assess liver health by measuring various enzymes, proteins, and substances in the blood. While not specific to liver cancer, abnormal LFT results may indicate liver damage or disease, prompting further diagnostic evaluation. Trends involve the utilization of LFTs as part of comprehensive liver health screening protocols and the incorporation of novel biomarkers to enhance diagnostic accuracy.
  • Biopsy: Liver biopsy involves the extraction of tissue samples from the liver for microscopic examination to confirm the presence of cancer cells and assess tumor characteristics. Trends include the adoption of minimally invasive biopsy techniques, such as ultrasound-guided or laparoscopic biopsies, to reduce patient discomfort and complications. Additionally, advancements in molecular analysis of biopsy specimens enable precise tumor characterization and personalized treatment selection.
  • Others: This category encompasses various emerging diagnostic modalities, including imaging techniques like MRI and CT scans, molecular diagnostics such as circulating tumor DNA analysis, and serological assays for detecting specific liver cancer biomarkers. Trends involve the development of non-invasive diagnostic methods to minimize patient discomfort and risks associated with invasive procedures, as well as the exploration of novel biomarkers and imaging biomarkers to improve diagnostic accuracy and prognostication.

By Application

  • Hospital-associated Labs: These labs are part of hospitals and healthcare facilities, offering diagnostic services primarily to inpatients and outpatients. Trends include increased integration of advanced imaging technologies, such as MRI and PET scans, within hospital settings, facilitating prompt diagnosis and treatment planning for liver cancer patients.
  • Independent Diagnostic Laboratories: These labs operate independently of hospitals and often cater to both healthcare providers and individual patients. Trends involve the adoption of innovative biomarker-based tests and molecular diagnostics for liver cancer screening, enabling more accurate and personalized diagnostic approaches.
  • Cancer Research Institutes: These institutes focus on advancing knowledge and developing new technologies for cancer diagnosis and treatment. Trends include the integration of cutting-edge genomic and proteomic technologies for liver cancer biomarker discovery and validation, driving the development of novel diagnostic assays with enhanced sensitivity and specificity.
  • Others: This category may include specialized clinics, academic medical centers, and government healthcare facilities. Trends encompass the implementation of multidisciplinary approaches to liver cancer diagnosis, involving collaboration between oncologists, radiologists, pathologists, and molecular biologists to optimize patient care and outcomes. Additionally, the trend towards telemedicine and remote diagnostic services may also impact this segment, enabling greater access to liver cancer diagnostics in underserved areas.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 9.2 Billion
Projected Market Size in 2033 USD 21.3 Billion
Market Size in 2023 USD 8.7 Billion
CAGR Growth Rate 6.6% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Test Type, End-User and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Liver Cancer Diagnostics Market – Regional Analysis

The Liver Cancer Diagnostics Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: This region includes the United States and Canada, characterized by advanced healthcare infrastructure and high adoption rates of innovative diagnostic technologies. Trends in North America involve the increasing prevalence of liver diseases due to factors such as obesity and alcohol consumption, driving demand for advanced liver cancer diagnostic tests. Additionally, there is a growing emphasis on personalized medicine approaches, with the integration of genetic testing and precision oncology techniques into clinical practice.
  • Europe: With a well-established healthcare system, Europe showcases a growing demand for liver cancer diagnostics fueled by the rising incidence of liver diseases, including viral hepatitis and non-alcoholic fatty liver disease. Trends include the adoption of population-based screening programs and the integration of artificial intelligence into diagnostic workflows to enhance accuracy and efficiency.
  • Asia-Pacific: This region, comprising countries like China, India, and Japan, experiences a significant burden of liver cancer due to factors like viral hepatitis infections and environmental toxins. Trends involve the expansion of healthcare infrastructure, especially in rural areas, to improve access to liver cancer diagnostics. Additionally, there is a growing focus on research and development, with local companies developing cost-effective diagnostic solutions tailored to the needs of the region.
  • LAMEA: LAMEA faces challenges such as limited access to healthcare services and a high prevalence of risk factors like viral hepatitis and aflatoxin exposure. Trends include efforts to improve healthcare infrastructure and increase awareness about liver cancer screening and diagnosis. Collaborations between governments, non-profit organizations, and international agencies aim to address these challenges, driving demand for affordable and accessible liver cancer diagnostics tailored to the region’s specific needs.

Global Liver Cancer Diagnostics Market 2024–2033 (By Billion)

www.custommarketinsight.com

Competitive Landscape – Liver Cancer Diagnostics Market

The Liver Cancer Diagnostics Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Bayer AG
  • BD (Becton Dickinson and Company)
  • Bio-Rad Laboratories Inc.
  • GE Healthcare
  • Illumina Inc.
  • Merck KGaA
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Sysmex Corporation
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships. Several new players are leveraging innovation and development to enter the liver cancer diagnostics market.

Startups and biotech firms are introducing novel technologies such as liquid biopsy assays, artificial intelligence algorithms for image analysis, and point-of-care diagnostic devices, aiming to disrupt the market with more accessible and accurate diagnostic solutions.

Key players dominating the liver cancer diagnostics market include established companies like Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers. These companies have extensive experience, global distribution networks, and robust research and development capabilities, allowing them to offer comprehensive diagnostic portfolios and maintain a competitive edge in the market. Their dominance is reinforced by strategic partnerships, regulatory approvals, and continuous innovation in diagnostic technologies.

The Liver Cancer Diagnostics Market is segmented as follows:

By Test Type

  • AFP Tests
  • LFTs
  • Biopsy
  • Others

By End-User

  • Hospital-associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Liver Cancer Diagnostics Market, (2024 – 2033) (USD Billion)
    • 2.2 Global Liver Cancer Diagnostics Market: snapshot
  • Chapter 3. Global Liver Cancer Diagnostics Market – Industry Analysis
    • 3.1 Liver Cancer Diagnostics Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Rising Incidence of Liver Cancer
      • 3.2.2 Technological Advancements
      • 3.2.3 Growing Adoption of Biomarker-Based Tests
      • 3.2.4 Increasing Awareness and Screening Initiatives
      • 3.2.5 Expanding Healthcare Infrastructure in Emerging Markets
      • 3.2.6 Strategic Collaborations and Partnerships.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Test Type
      • 3.7.2 Market Attractiveness Analysis By End-User
  • Chapter 4. Global Liver Cancer Diagnostics Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Liver Cancer Diagnostics Market: company market share, 20223
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Liver Cancer Diagnostics Market – Test Type Analysis
    • 5.1 Global Liver Cancer Diagnostics Market Overview: By Test Type
      • 5.1.1 Global Liver Cancer Diagnostics Market Share, By Test Type, 20223 and 2033
    • 5.2 AFP Tests
      • 5.2.1 Global Liver Cancer Diagnostics Market by AFP Tests, 2024 – 2033 (USD Billion)
    • 5.3 LFTs
      • 5.3.1 Global Liver Cancer Diagnostics Market by LFTs, 2024 – 2033 (USD Billion)
    • 5.4 Biopsy
      • 5.4.1 Global Liver Cancer Diagnostics Market by Biopsy, 2024 – 2033 (USD Billion)
    • 5.5 Others
      • 5.5.1 Global Liver Cancer Diagnostics Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 6. Global Liver Cancer Diagnostics Market – End-User Analysis
    • 6.1 Global Liver Cancer Diagnostics Market Overview: By End-User
      • 6.1.1 Global Liver Cancer Diagnostics Market Share, By End-User, 20223 and 2033
    • 6.2 Hospital-associated Labs
      • 6.2.1 Global Liver Cancer Diagnostics Market by Hospital-associated Labs, 2024 – 2033 (USD Billion)
    • 6.3 Independent Diagnostic Laboratories
      • 6.3.1 Global Liver Cancer Diagnostics Market by Independent Diagnostic Laboratories, 2024 – 2033 (USD Billion)
    • 6.4 Cancer Research Institutes
      • 6.4.1 Global Liver Cancer Diagnostics Market by Cancer Research Institutes, 2024 – 2033 (USD Billion)
    • 6.5 Others
      • 6.5.1 Global Liver Cancer Diagnostics Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 7. Liver Cancer Diagnostics Market – Regional Analysis
    • 7.1 Global Liver Cancer Diagnostics Market Regional Overview
    • 7.2 Global Liver Cancer Diagnostics Market Share, by Region, 20223 & 2033 (USD Billion)
    • 7.3. North America
      • 7.3.1 North America Liver Cancer Diagnostics Market, 2024 – 2033 (USD Billion)
        • 7.3.1.1 North America Liver Cancer Diagnostics Market, by Country, 2024 – 2033 (USD Billion)
    • 7.4 North America Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033
      • 7.4.1 North America Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033 (USD Billion)
    • 7.5 North America Liver Cancer Diagnostics Market, by End-User, 2024 – 2033
      • 7.5.1 North America Liver Cancer Diagnostics Market, by End-User, 2024 – 2033 (USD Billion)
    • 7.6. Europe
      • 7.6.1 Europe Liver Cancer Diagnostics Market, 2024 – 2033 (USD Billion)
        • 7.6.1.1 Europe Liver Cancer Diagnostics Market, by Country, 2024 – 2033 (USD Billion)
    • 7.7 Europe Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033
      • 7.7.1 Europe Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033 (USD Billion)
    • 7.8 Europe Liver Cancer Diagnostics Market, by End-User, 2024 – 2033
      • 7.8.1 Europe Liver Cancer Diagnostics Market, by End-User, 2024 – 2033 (USD Billion)
    • 7.9. Asia Pacific
      • 7.9.1 Asia Pacific Liver Cancer Diagnostics Market, 2024 – 2033 (USD Billion)
        • 7.9.1.1 Asia Pacific Liver Cancer Diagnostics Market, by Country, 2024 – 2033 (USD Billion)
    • 7.10 Asia Pacific Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033
      • 7.10.1 Asia Pacific Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033 (USD Billion)
    • 7.11 Asia Pacific Liver Cancer Diagnostics Market, by End-User, 2024 – 2033
      • 7.11.1 Asia Pacific Liver Cancer Diagnostics Market, by End-User, 2024 – 2033 (USD Billion)
    • 7.12. Latin America
      • 7.12.1 Latin America Liver Cancer Diagnostics Market, 2024 – 2033 (USD Billion)
        • 7.12.1.1 Latin America Liver Cancer Diagnostics Market, by Country, 2024 – 2033 (USD Billion)
    • 7.13 Latin America Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033
      • 7.13.1 Latin America Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033 (USD Billion)
    • 7.14 Latin America Liver Cancer Diagnostics Market, by End-User, 2024 – 2033
      • 7.14.1 Latin America Liver Cancer Diagnostics Market, by End-User, 2024 – 2033 (USD Billion)
    • 7.15. The Middle-East and Africa
      • 7.15.1 The Middle-East and Africa Liver Cancer Diagnostics Market, 2024 – 2033 (USD Billion)
        • 7.15.1.1 The Middle-East and Africa Liver Cancer Diagnostics Market, by Country, 2024 – 2033 (USD Billion)
    • 7.16 The Middle-East and Africa Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033
      • 7.16.1 The Middle-East and Africa Liver Cancer Diagnostics Market, by Test Type, 2024 – 2033 (USD Billion)
    • 7.17 The Middle-East and Africa Liver Cancer Diagnostics Market, by End-User, 2024 – 2033
      • 7.17.1 The Middle-East and Africa Liver Cancer Diagnostics Market, by End-User, 2024 – 2033 (USD Billion)
  • Chapter 8. Company Profiles
    • 8.1 Abbott Laboratories
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 Agilent Technologies Inc.
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 Bayer AG
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 BD (Becton Dickinson and Company)
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Bio-Rad Laboratories Inc.
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 GE Healthcare
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 Illumina Inc.
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 Merck KGaA
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 PerkinElmer Inc.
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments
    • 8.10 QIAGEN N.V.
      • 8.10.1 Overview
      • 8.10.2 Financials
      • 8.10.3 Product Portfolio
      • 8.10.4 Business Strategy
      • 8.10.5 Recent Developments
    • 8.11 Roche Diagnostics
      • 8.11.1 Overview
      • 8.11.2 Financials
      • 8.11.3 Product Portfolio
      • 8.11.4 Business Strategy
      • 8.11.5 Recent Developments
    • 8.12 Siemens Healthineers
      • 8.12.1 Overview
      • 8.12.2 Financials
      • 8.12.3 Product Portfolio
      • 8.12.4 Business Strategy
      • 8.12.5 Recent Developments
    • 8.13 Thermo Fisher Scientific Inc.
      • 8.13.1 Overview
      • 8.13.2 Financials
      • 8.13.3 Product Portfolio
      • 8.13.4 Business Strategy
      • 8.13.5 Recent Developments
    • 8.14 Tosoh Corporation
      • 8.14.1 Overview
      • 8.14.2 Financials
      • 8.14.3 Product Portfolio
      • 8.14.4 Business Strategy
      • 8.14.5 Recent Developments
    • 8.15 Sysmex Corporation
      • 8.15.1 Overview
      • 8.15.2 Financials
      • 8.15.3 Product Portfolio
      • 8.15.4 Business Strategy
      • 8.15.5 Recent Developments
    • 8.16 Others.
      • 8.16.1 Overview
      • 8.16.2 Financials
      • 8.16.3 Product Portfolio
      • 8.16.4 Business Strategy
      • 8.16.5 Recent Developments
List Of Figures

Figures No 1 to 22

List Of Tables

Tables No 1 to 52

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Bayer AG
  • BD (Becton Dickinson and Company)
  • Bio-Rad Laboratories Inc.
  • GE Healthcare
  • Illumina Inc.
  • Merck KGaA
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Sysmex Corporation
  • Others

FAQs

The key factors driving the Market are Rising Incidence of Liver Cancer, Technological Advancements, Growing Adoption of Biomarker-Based Tests, Increasing Awareness and Screening Initiatives, Expanding Healthcare Infrastructure in Emerging Markets, Strategic Collaborations and Partnerships.

The “AFP Tests” category dominated the market in 2023.

The key players in the market are Abbott Laboratories, Agilent Technologies Inc., Bayer AG, BD (Becton Dickinson and Company), Bio-Rad Laboratories Inc., GE Healthcare, Illumina Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N.V., Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific Inc., Tosoh Corporation, Sysmex Corporation, Others.

“Asia-Pacific” had the largest share in the Liver Cancer Diagnostics Market.

The global market is projected to grow at a CAGR of 6.6% during the forecast period, 2024-2033.

The Liver Cancer Diagnostics Market size was valued at USD 9.2 Billion in 2024.

PURCHASE OPTIONS

$

3990


$

4990


$

5990


$

2290


$

2390

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • Report in your Language.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Report in your Language.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • In-Depth Company Profiles.
  • SWOT Analysis.
  • Identify your Competitors.
  • Recent Development Analysis.
  • Competitor Pricing Strategies.
  • Competitor Marketing Strategies.
  • Competitor Positioning and Messaging.
  • Competitor Product’s Strengths.
  • Free 20% or 10 Hours of Customisation.
  • 15% Discount on your Next Purchase.
  • Upgradable to other licenses.
  • PDF Format.
  • Permission to Print the Report.

Want to customize this report?
100% FREE CUSTOMIZATION!